|
000
| 01960nam 2200313za 4500 |
|---|
| 001 | 9.833934 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107150326 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 170327s2016 oncd os f000 0 eng d |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 041 | 0 |aeng|afre |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH82-25/2016-PDF |
|---|
| 245 | 00|aCost pressure of the new hepatitis C drugs in Canada |h[electronic resource] = |bPressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada. |
|---|
| 246 | 31|aPressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada |
|---|
| 260 | |a[Ottawa] : |bPatented Medicine Prices Review Board, |c[2016] |
|---|
| 300 | |a[1] p. : |bcol. charts |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |aAt head of title: National Prescription Drug Utilization Information System. |
|---|
| 520 | |a"The pricing, utilization and cost related to the direct-acting antivirals (DAAs) for the treatment of hepatitis C has become a critical issue for public plans, private insurers and patients. This study provides insight into the use, pricing and cost of DAAs in Canada and internationally in 2015, along with a retrospective look at the recent trends. The international analysis focuses on the PMPRB7 countries: France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the United States (US). Results for the Canadian market are reported at the national level, as well as for the private and public market segments." |
|---|
| 546 | |aText in English and French. |
|---|
| 692 | 07|2gccst|aHepatitis |
|---|
| 692 | 07|2gccst|aDrugs |
|---|
| 692 | 07|2gccst|aPrices |
|---|
| 710 | 1 |aCanada. |bPatented Medicine Prices Review Board. |
|---|
| 710 | 2 |aNational Prescription Drug Utilization Information System (Canada) |
|---|
| 792 | |tCost pressure of the new hepatitis C drugs in Canada |w(CaOODSP)9.833936 |
|---|
| 856 | 40|qPDF|s313 KB|uhttps://publications.gc.ca/collections/collection_2017/cepmb-pmprb/H82-25-2016.pdf |
|---|